Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097982 | 0.85 | ACP3 (0.37) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL2098296 | 0.84 | TRPV1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2099777 | 0.84 | GRM5 (0.33) | TRPM8LMNATSHRSMN1; SMN2 | |
| SCHEMBL2098702 | 0.83 | POLB (0.36) | MEN1KMT2ALMNASMN1; SMN2TDP1 | |
| SCHEMBL2101140 | 0.82 | ACP3 (0.34) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2098841 | 0.82 | MEN1 (0.41) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL3064033 | 0.81 | MEN1 (0.31) | MEN1KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL3051590 | 0.81 | MEN1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2055511 | 0.81 | TRPM8 (0.37) | TRPM8MEN1KMT2A | |
| SCHEMBL2101813 | 0.79 | ITGA4 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | ARSA, SULT2A1, PMM2 | TRPM8 4508/4885MEN1 2590/4885KMT2A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.